Fibrocell Science, Inc.

The odds of having an approved therapy for epidermolysis bullosa (EB) by the end of 2021 have improved with the news that US regulators have fast-tracked Amryt Pharma 's Oleogel-S10 but gene therapie

Stock market volatility due to business interruptions caused by the novel coronavirus has brought most fundraising by public companies to a halt, but so far COVID-19 hasn’t slowed the flow of venture

Jeffrey Aronin, the former CEO of Marathon Pharmaceuticals LLC , has been building a portfolio of new drug companies under the Paragon Biosciences LLC umbrella over the last two years, with a focus

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions . Fibrocell Finds New Life In